CSIMarket



Immucell Corp  (ICCC)
Other Ticker:  
 

Cumulative Immucell's Working Capital Ratio for Trailing Twelve Months Period

ICCC's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ICCC Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Current Liabilities Growth 23.46 % 12.05 % 14.63 % 20.2 % -14.47 %
Y / Y Current Assets Growth 11.56 % 54.95 % 33.79 % 61.77 % 37.18 %
Working Capital Ratio for Trailing Twelve Months Period 7.11 7.28 6.76 6.53 6.07
Total Ranking # 773 # 784 # 905 # 726 # 768
Seq. Current Liabilities Growth 6.71 % -7.24 % 17.03 % 6.57 % -3.15 %
Seq. Current Assets Growth -5.3 % 12.51 % 1.18 % 3.5 % 31.52 %


Working Capital Ratio for Trailing Twelve Months Period Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the II. Quarter to $3 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 7.11 below Immucell Corp average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Immucell. While Working Capital Ratio for Trailing Twelve Months Period overall ranking has improved so far to 773, from total ranking in previous quarter at 784.

What is Working Capital Ratio?
More about ICCC
Working Capital Ratio ICCC in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 6
Sector # 376
S&P 500 # 761


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.22 6.95 2.5
(Sep 30 2016)   (Mar 31 2018)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2022, within In Vitro & In Vivo Diagnostic Substances Industry Working Capital Ratio for Trailing Twelve Months Period
Celldex Therapeutics inc.  18.49 
Arca Biopharma Inc.  17.67 
Neogen Corporation  9.83 
Achieve Life Sciences Inc.  8.53 
Heska Corporation  7.45 
Intellia Therapeutics Inc.  7.44 
Immucell Corp  7.42 
Aspira Women s Health Inc.  6.16 
Lucira Health Inc.  4.93 
Meridian Bioscience Inc.  4.08 
Quotient Limited  3.79 
Quidelortho Corp  3.02 
Oncocyte Corporation  2.80 
Myriad Genetics Inc.  2.30 
Volitionrx Limited  2.13 
Lantheus Holdings Inc.  2.04 
Ortho Clinical Diagnostics Holdings Plc  1.88 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PROV's Profile

Stock Price

PROV's Financials

Business Description

Fundamentals

Charts & Quotes

PROV's News

Suppliers

PROV's Competitors

Customers & Markets

Economic Indicators

PROV's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071